Description
Referenced Citations
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 - Marso, S.P., et al. (2016). GLP-1 and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19), 1834-1844. [Online].
Available: https://pubmed.ncbi.nlm.nih.gov/27633186/ - Bachem. (2024). GLP-1 Peptide API Manufacturer & Supply. [Online].
Available: https://www.bachem.com/all-generic-apis/semaglutide/ - Smits, M.M., and Van Raalte, D.H. (2021). Safety of GLP-1. Front Endocrinol, 12, 1-19. [Online].
Available: https://www.frontiersin.org/articles/10.3389/fendo.2021.645563/full - Aroda, V.R., et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral GLP-1 Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724-1732. [Online].
Available: https://pubmed.ncbi.nlm.nih.gov/31186300/